In October 2020 Pfizer stopped analyzing nasal swabs from patients with suspected COVID in their vaccine trial. If they had analyzed these swabs and reached a cumulative total of 32 infections they would have been required to notify the FDA and the security exchange commission and had to disclose vaccine was very effective. On November 3 they began analyzing the nasal swabs and found they had 94 cumulative cases and on November 8 they publicly announced the positive results from the vaccine trial.
For some reason Pfizer, after talking with the FDA, decided to try to change the trial design for the first efficacy evaluation from 32 cases to 62 cases. However, until this change was approved by the FDA, Pfizer would have been required to evaluate efficacy at 32 cases. Pfizer would have known that they would reach the 32 cases well before the election and have been required to publicly disclose the efficacy of the vaccine and they would have known that stopping the analysis of nasal swabs would prevent them from getting to 32 cases.
What happened? The study change from initial efficacy evaluation from 32 to 62 cases was approved November 3. By November 8 they publicly disclosed that they had 93 cases, well above the 32 threshold and even above the 62 threshold.
Of course they claim there was no political motivation for this and they had no discussions with the FDA about this. Given they are saying it will take them 26 years to produce the documents related to their vaccine approval required by FOI requests, one has to wonder.
It is estimated that the delay in vaccine approval caused by their intentional delay of analyzing nasal swabs was about two months and may have resulted in 50,000 additional deaths.
No comments:
Post a Comment